Edition:
Deutschland

Allergan plc (AGN.N)

AGN.N on New York Stock Exchange

187.09USD
19:37 Uhr
Change (% chg)

$4.14 (+2.26%)
Prev Close
$182.95
Open
$184.40
Day's High
$187.21
Day's Low
$183.40
Volume
120,929
Avg. Vol
475,661
52-wk High
$206.78
52-wk Low
$142.83

AGN.N

Chart for AGN.N

About

Allergan plc is a specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of brand name pharmaceutical products, medical aesthetics, biosimilar and over-the-counter pharmaceutical products. The Company operates through three segments: US Specialized Therapeutics, US... (more)

Buy/Sell

Sell Hold Buy
2.05 Mean rating from 22 analysts

Overall

Beta: 1.17
Market Cap(Mil.): $69,117.80
Shares Outstanding(Mil.): 334.31
Dividend: 0.70
Yield (%): 1.35

UPDATE 1-U.S. FDA approves Lilly migraine drug; price same as rivals

NEW YORK, Sept 27 Eli Lilly and Co on Thursday said the U.S. Food and Drug Administration approved its migraine drug Emgality, marking the third approval from a promising new class of treatments for the often debilitating headaches.

Lilly migraine drug wins European panel thumbs-up

Sept 21 A European Medicines Agency panel on Friday recommended the approval of U.S. pharmaceutical group Eli Lilly's migraine treatment, bringing the drug one step closer to being sold in the European Union.

Photo

Allergan says revenue from aesthetics unit may double by 2025

NEW YORK Allergan Plc said revenue from its medical aesthetics business could double by 2025, even as it faces increasing competition for its blockbuster wrinkle treatment, Botox.

CORRECTED-UPDATE 1-Allergan says revenue from aesthetics unit may double by 2025

NEW YORK, Sept 14 Allergan Plc said revenue from its medical aesthetics business could double by 2025, even as it faces increasing competition for its blockbuster wrinkle treatment, Botox.

Allergan says aesthetics unit revenue may double by 2025

NEW YORK, Sept 14 Allergan Plc said it expects revenue at its medical aesthetics unit to grow to $7 to $8 billion by 2025, even as it faces increasing competition for its blockbuster wrinkle treatment, Botox.

UPDATE 1-U.S. FDA approves Tetraphase Pharma's antibiotic

Aug 27 Tetraphase Pharmaceuticals Inc said on Monday U.S. health regulators approved its drug to treat complicated intra-abdominal infections, providing a new option to combat the growing threat from treatment-resistant bacteria.

UPDATE 1-FDA rejects Allergan's Esmya fibroid treatment

Aug 21 Allergan Plc said on Tuesday U.S. health regulators had declined to approve Esmya, its treatment for abnormal uterine bleeding in women with uterine fibroids, requesting more information and citing safety issues outside the United States.

FDA declines to approve Allergan's Esmya

Aug 21 Allergan Plc said on Tuesday U.S. health regulators had declined to approve Esmya, its treatment for abnormal uterine bleeding in women with uterine fibroids, requesting more information and citing safety issues outside the United States.

RPT-U.S. tax cuts prompt rethink by some 'inverted' companies

WASHINGTON, Aug 3 A few U.S. companies that moved offshore in a wave of inversion deals are considering returning to the United States now that domestic tax rates are lower and tax policing is tougher abroad, attorneys and consultants said.

Märkte

  • U.S.
  • Europa
  • Asien
  • Branchen

Branchenüberblick

Energie +1.07%
Rohstoffe +1.46%
Industrie +1.70%
Konjunktur abhängige Waren & Dienstleistungen +0.54%
Konjunktur unabhängige Waren & Dienstleistungen +1.15%
Finanzindustrie +2.21%
Pharma +2.58%
Technologie +1.02%
Telekommunikation +1.36%